OPK
OPKO Health, Inc. NASDAQ Listed Nov 2, 1995$1.12
Mkt Cap $845.7M
52w Low $0.98
22.6% of range
52w High $1.60
50d MA $1.17
200d MA $1.31
P/E (TTM)
-3.8x
EV/EBITDA
-21.2x
P/B
0.7x
Debt/Equity
0.3x
ROE
-1.5%
P/FCF
-5.1x
RSI (14)
—
ATR (14)
—
Beta
1.49
50d MA
$1.17
200d MA
$1.31
Avg Volume
2.5M
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
4400 Biscayne Boulevard · Miami, FL 33137 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | AMC | -0.07 | -0.07 | +0.0% | 1.21 | -3.3% | -8.3% | +1.8% | -2.7% | +0.9% | +0.9% | — |
| Feb 26, 2026 | AMC | -0.07 | -0.04 | +42.9% | 1.20 | -0.8% | +0.0% | +3.3% | -4.0% | +0.8% | -2.5% | — |
| Oct 29, 2025 | AMC | -0.02 | 0.03 | +250.0% | 1.43 | -2.1% | +2.1% | -6.8% | +2.9% | -0.7% | -3.6% | — |
| Jul 31, 2025 | AMC | -0.12 | -0.19 | -58.3% | 1.28 | -4.7% | -7.0% | +6.7% | -0.8% | +0.8% | -3.1% | — |
| Apr 30, 2025 | AMC | -0.06 | -0.10 | -66.7% | 1.38 | -5.1% | -2.2% | +3.0% | -2.2% | -5.9% | -2.3% | — |
| Feb 27, 2025 | AMC | -0.08 | 0.01 | +112.5% | 1.63 | +4.3% | +6.7% | +0.6% | +9.7% | +1.0% | -2.6% | — |
| Nov 7, 2024 | AMC | -0.10 | 0.03 | +130.0% | 1.45 | +0.7% | +4.8% | +3.3% | +2.5% | -0.6% | +1.2% | — |
| Aug 7, 2024 | AMC | -0.09 | -0.01 | +88.9% | 1.28 | +6.2% | +11.7% | +4.9% | +0.0% | +1.3% | +0.7% | — |
| May 7, 2024 | AMC | -0.09 | -0.12 | -33.3% | 1.30 | -10.0% | -3.8% | +0.8% | +1.6% | -1.6% | +4.0% | — |
| Feb 27, 2024 | AMC | -0.09 | -0.09 | +0.0% | 1.05 | -4.8% | -6.1% | +1.5% | -0.7% | +0.7% | -6.5% | — |
| Nov 6, 2023 | AMC | -0.09 | -0.11 | -22.2% | 1.34 | -3.0% | +0.0% | +0.0% | -4.5% | -1.6% | +1.6% | — |
| Aug 3, 2023 | AMC | -0.07 | -0.03 | +57.1% | 1.85 | +7.0% | +7.6% | -8.5% | +3.3% | -5.9% | +2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Barrington Research | Downgrade | Outperform → Mkt Perform | — | $1.21 | $1.17 | -3.3% | -8.3% | +1.8% | -2.7% | +0.9% | +1.8% |
| Apr 29 | Barrington Research | Downgrade | Outperform → Market Perform | — | $1.21 | $1.17 | -3.3% | -8.3% | +1.8% | -2.7% | +0.9% | +1.8% |
| Mar 2 | Barrington Research | Maintains | Outperform → Outperform | — | $1.20 | $1.19 | -0.8% | +3.3% | -4.0% | +0.8% | -2.5% | +0.9% |
| Oct 31 | Jefferies | Downgrade | Buy → Hold | — | $1.46 | $1.42 | -2.7% | -6.8% | +2.9% | -0.7% | -3.6% | +3.0% |
| Oct 30 | Barrington Research | Maintains | Outperform → Outperform | — | $1.43 | $1.40 | -2.1% | +2.1% | -6.8% | +2.9% | -0.7% | -3.6% |
| May 1 | Barrington Research | Maintains | Outperform → Outperform | — | $1.38 | $1.31 | -5.1% | -2.2% | +3.0% | -2.2% | -5.9% | -2.3% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.55 | $1.50 | -3.2% | -1.3% | -4.6% | +2.1% | -8.7% | +4.4% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.76 | -1.7% | +3.9% | -2.2% | -1.1% | +0.6% | -0.6% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.83 | +1.7% | -1.1% | -3.4% | +1.2% | +4.0% | -1.1% |
| Mar 12 | Barrington Research | Maintains | Outperform → Outperform | — | $1.80 | $1.83 | +1.7% | -1.1% | -3.4% | +1.2% | +4.0% | -1.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.75 | +0.6% | +0.6% | +9.7% | +1.0% | -2.6% | +0.5% |
| Feb 28 | Barrington Research | Maintains | Outperform → Outperform | — | $1.63 | $1.70 | +4.3% | +6.7% | +0.6% | +9.7% | +1.0% | -2.6% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.49 | -1.3% | -2.0% | -0.7% | +4.1% | -3.3% | -0.7% |
| Nov 8 | Barrington Research | Maintains | Outperform → Outperform | — | $1.45 | $1.46 | +0.7% | +4.8% | +3.3% | +2.5% | -0.6% | +1.2% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.49 | +0.7% | +0.7% | +2.0% | -2.0% | +0.0% | +2.0% |
| Sep 20 | Barrington Research | Maintains | Outperform → Outperform | — | $1.59 | $1.55 | -2.5% | -6.9% | +1.4% | -1.3% | +0.0% | +0.7% |
| Sep 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.64 | $1.55 | -5.5% | +1.2% | -2.4% | -1.9% | -6.9% | +1.4% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.55 | -5.5% | +1.2% | -2.4% | -1.9% | -6.9% | +1.4% |
| Aug 8 | Barrington Research | Maintains | Outperform → Outperform | — | $1.28 | $1.36 | +6.2% | +11.7% | +4.9% | +0.0% | +1.3% | +0.7% |
| Jul 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.42 | $1.53 | +7.7% | +7.0% | -2.0% | -2.0% | -1.4% | -1.4% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.17 | -10.0% | -3.8% | +0.8% | +1.6% | -1.6% | +4.0% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.33 | -1.5% | +0.0% | +0.7% | -0.7% | +3.7% | -1.4% |
| Apr 1 | Barrington Research | Maintains | Outperform → Outperform | — | $1.20 | $1.20 | +0.0% | +9.2% | +3.1% | +0.0% | +0.7% | -0.7% |
| Apr 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.20 | $1.20 | +0.0% | +9.2% | +3.1% | +0.0% | +0.7% | -0.7% |
| Feb 28 | Barrington Research | Maintains | Outperform → Outperform | — | $1.05 | $1.00 | -4.8% | -6.1% | +1.5% | -0.7% | +0.7% | -6.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.05 | $1.00 | -4.8% | -6.1% | +1.5% | -0.7% | +0.7% | -6.5% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.99 | $2.02 | +1.5% | -8.5% | +3.3% | -5.9% | +2.8% | -0.5% |
| Jun 29 | Barrington Research | Upgrade | Market Perform → Outperform | — | $1.72 | $1.72 | +0.0% | +13.7% | +11.0% | -1.8% | -1.4% | -1.9% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.71 | +1.2% | +8.3% | +1.6% | -0.5% | -1.1% | -2.7% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +7.1% | +2.5% | +0.8% | +7.2% | +1.5% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.12 | $1.08 | -3.6% | -5.4% | +6.6% | +0.9% | +2.6% | +2.6% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.29 | $1.31 | +1.6% | -3.1% | +0.0% | -8.0% | +2.6% | -0.8% |
| Aug 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.40 | $2.30 | -4.2% | -5.0% | +7.5% | +2.4% | +8.0% | -7.7% |
| May 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.44 | $2.55 | +4.5% | +20.1% | -8.2% | +4.1% | +8.2% | -2.0% |
| Jan 24 | Barrington Research | Downgrade | Outperform → Market Perform | — | $4.24 | $3.53 | -16.7% | -23.8% | -6.8% | -3.3% | -1.4% | +2.8% |
| Jun 21 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3.70 | $3.76 | +1.6% | +2.2% | +1.6% | -3.6% | +1.9% | +2.4% |
| Nov 25 | Piper Jaffray | Maintains | Overweight → Overweight | — | $1.61 | $1.65 | +2.5% | +1.2% | -2.5% | +1.3% | -1.2% | -1.9% |
| Mar 2 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.18 | $2.67 | -16.0% | +6.0% | +5.0% | -3.4% | -2.6% | -0.3% |
| Sep 14 | JP Morgan | Downgrade | Overweight → Neutral | — | $6.47 | $6.24 | -3.6% | -7.0% | -0.8% | +0.8% | -0.2% | +5.3% |
| Aug 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.88 | $6.07 | +3.2% | +4.1% | +0.3% | +0.8% | -1.0% | +2.8% |
| Mar 14 | Guggenheim | Maintains | Buy → Buy | — | $7.92 | $8.14 | +2.8% | +1.9% | +0.2% | +3.3% | -2.9% | -1.5% |
| Dec 30 | Standpoint Research | Maintains | Buy → Buy | — | $11.46 | $9.71 | -15.3% | -18.8% | -2.3% | +2.0% | -2.5% | +3.8% |
| Jun 16 | Deutsche Bank | Maintains | Hold → Hold | — | $9.23 | $9.07 | -1.7% | +0.5% | -2.5% | +1.5% | +5.5% | -3.5% |
| Jun 3 | Standpoint Research | Maintains | Buy → Buy | — | $10.65 | $10.64 | -0.1% | -6.0% | +0.2% | -1.4% | -1.1% | -1.7% |
| Mar 31 | Barrington Research | Maintains | Outperform → Outperform | — | $9.90 | $9.96 | +0.6% | +4.9% | +0.2% | -0.1% | -1.2% | +3.9% |
| Oct 16 | JP Morgan | Maintains | Overweight → Overweight | — | $9.28 | $9.59 | +3.3% | +1.2% | +8.1% | -6.2% | -3.9% | -1.3% |
| Aug 12 | Laidlaw & Co. | Maintains | Buy → Buy | — | $13.45 | $13.40 | -0.4% | +0.0% | -2.8% | -0.6% | +1.1% | -3.0% |
| Mar 3 | Oppenheimer | Downgrade | Outperform → Perform | — | $14.44 | $14.05 | -2.7% | -0.3% | -0.2% | -0.3% | -1.5% | -0.9% |
| Aug 13 | Jefferies | Maintains | Buy → Buy | — | $9.08 | $9.12 | +0.4% | +1.1% | -0.8% | -0.3% | +1.0% | -1.2% |
| May 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.24 | $8.22 | -0.2% | +2.1% | -1.0% | -1.8% | -0.1% | +0.0% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A board member change at OPK suggests potential shifts in healthcare industry expertise and strategic direction, which investors should monitor for impacts on company governance and operational focus.
Mar 19
8-K
Opko Health Inc. -- 8-K Filing
OPKO Health reported fourth-quarter 2025 results and is hosting a conference call to discuss financial performance and business developments with investors.
Feb 26
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.
Feb 4
Data updated apr 26, 2026 5:40pm
· Source: massive.com